pRM049 His-TEV-Cas9 triNLS 2C
(Plasmid
#196245)
-
PurposeExpression of NLS-rich Cas9 (2 Cys residues, mammalian codon optimized)
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 196245 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepEC-K-MBP
-
Backbone manufacturerpET-based custom vector
- Backbone size w/o insert (bp) 6400
- Total vector size (bp) 9073
-
Modifications to backboneMBP removed
-
Vector typeBacterial Expression, CRISPR
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameCas9
-
Alt nameCas9-2C-triNLS
-
SpeciesStreptococcus pyogenes
-
Insert Size (bp)4102
-
Tags
/ Fusion Proteins
- His6 (N terminal on backbone) (N terminal on insert)
- HA (C terminal on insert)
- SV40 (C terminal on insert)
- Nucleoplasmin (C terminal on insert)
- NLS (N terminal on insert)
Cloning Information
- Cloning method Gibson Cloning
- 5′ sequencing primer T7 promoter
- 3′ sequencing primer T7 terminator (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made bypMJ806 was a gift from Jennifer Doudna (Addgene plasmid # 39312 ; http://n2t.net/addgene:39312 ; RRID:Addgene_39312)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pRM049 His-TEV-Cas9 triNLS 2C was a gift from Ross Wilson (Addgene plasmid # 196245 ; http://n2t.net/addgene:196245 ; RRID:Addgene_196245) -
For your References section:
Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes. Foss DV, Muldoon JJ, Nguyen DN, Carr D, Sahu SU, Hunsinger JM, Wyman SK, Krishnappa N, Mendonsa R, Schanzer EV, Shy BR, Vykunta VS, Allain V, Li Z, Marson A, Eyquem J, Wilson RC. Nat Biomed Eng. 2023 May;7(5):647-660. doi: 10.1038/s41551-023-01032-2. Epub 2023 Apr 25. 10.1038/s41551-023-01032-2 PubMed 37147433